# Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients

> **NCT02732938** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** PF-04136309
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT02732938
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-05-04
- **Primary completion:** 2017-09-15
- **Final completion:** 2017-10-10
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Pfizer made a business-related decision on 04May2017 to terminate study based on change in portfolio prioritization, and is not due to safety or efficacy.
- **Last updated:** 2019-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02732938

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02732938, "Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02732938. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*